Not bad for nine months' work. Mylan CEO and Vice Chairman Robert Coury (photo [1]) brought down $10.3 million during fiscal 2007, which ran only nine months because the drugmaker changed its fiscal year.

Coury earned salary of about $1.12 million, stock awards of $1.15 million, and about $2.1 million in incentive compensation, the Pittsburgh Business Times reports. During the previous fiscal year, Coury was paid about $8.6 million. How does this compare to other drugmakers' executive pay? Well, it beats Pfizer's Jeff Kindler ($9.5 million [2]) but doesn't outstrip Bristol-Myers Squibb's Jim Cornelius ($11.3 million [3]) or even Cephalon's Frank Baldino ($13.5 million [4]).

- read the Business Times story [5]

ALSO: A federal appeals court affirmed a ruling that prevents Mylan from selling a copycat form of Johnson & Johnson's Topamax before the epilepsy med's patent expires later this year. Report [6]

Related Articles:
Mylan CEO intent on new global biz. Report [7]
Glaxo to let Mylan make generic Paxil. Report [8]